Novartis had not factored the European pre-taxane indication in its $5 billion peak sales estimate for Pluvicto because it had anticipated challenge with regulators, CEO Vas Narasimhan said. (Novartis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results